Peptide biotech stocks
Every publicly traded peptide biotech, in one dashboard.
Pipelines, clinical trials, FDA catalysts, and financial disclosures for the companies developing peptide-based therapies — sourced from SEC EDGAR, ClinicalTrials.gov, and FDA.
Last updated:Jul 15, 2026Source:SEC EDGAR, ClinicalTrials.gov, FDA.govVerified:Manually reviewed by PeptidePlanet research teamData provider:PeptidePlanet Research
Mega- to micro-cap coverage
Eli Lilly and Novo Nordisk down to small-cap developers like Viking and Structure Therapeutics.
Verified sources on every profile
Each company page cites IR pages, 10-Ks, and clinical registries with last-updated dates.
Pipeline & catalyst tracking
See upcoming readouts, PDUFA dates, and Phase 3 milestones in one calendar.
Newsletter
Get the weekly PeptidePlanet brief.
Free weekly digest of peptide biotech catalysts, trial readouts, and FDA calendar events.
No spam. Unsubscribe anytime.
Frequently asked questions
- What is a peptide biotech stock?
- A peptide biotech stock is a publicly traded pharmaceutical or biotechnology company whose pipeline is meaningfully composed of peptide-based drug candidates — such as GLP-1 receptor agonists, oncology peptides, or peptide-drug conjugates.
- Which peptide biotech companies are largest by market cap?
- Eli Lilly (LLY) and Novo Nordisk (NVO) are the two dominant peptide-therapeutics companies by market capitalization, driven by their GLP-1 franchises (Mounjaro/Zepbound, Ozempic/Wegovy). Amgen, Viking Therapeutics, and Structure Therapeutics are frequently discussed mid- and small-cap names.
- How does PeptidePlanet cover these stocks?
- PeptidePlanet aggregates public data from SEC EDGAR, ClinicalTrials.gov, and FDA sources into a single dashboard. Every company profile links back to verified primary sources with last-updated dates.
- Is this investment advice?
- No. PeptidePlanet is an educational research platform. Nothing on this site is a recommendation to buy or sell securities.